XM does not provide services to residents of the United States of America.
K
K

Kroger

News

US FTC preparing to sue to block $8.5 bln takeover of Capri by Tapestry, NYT Dealbook reports

UPDATE 3-US FTC preparing to sue to block $8.5 bln takeover of Capri by Tapestry, NYT Dealbook reports Adds background and FTC's response in paragraphs 5,7 & 9, updates shares in paragraph 10 By Savyata Mishra April 17 (Reuters) - The U.S. Federal Trade Commission (FTC) is preparing to sue to block Coach parent Tapestry's TPR.N $8.5 billion deal to buy Michael Kors owner Capri CPRI.N , NYT Dealbook reported on Wednesday, citing people familiar with the matter.
K

U.S. STOCKS US Health Insurers, Palisade Bio, Dynatronics

BUZZ-U.S. STOCKS ON THE MOVE-US Health Insurers, Palisade Bio, Dynatronics Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes were on track for a higher open on Tuesday, with health insurers leading the charge following upbeat results from industry major UnitedHealth, while investors kept tabs on the conflict in the Middle East.
B
C
J
K
S
T
U
L

U.S. STOCKS Macatawa Bank, Kroger, International Paper

BUZZ-U.S. STOCKS ON THE MOVE-Macatawa Bank, Kroger, International Paper Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures edged lower on Tuesday, weighed by elevated Treasury yields as investors remained wary of the conflict in the Middle East, turning the lens on company earnings to gauge the strength of the economy.
B
J
K
S
U
L

Wells Fargo upgrades Kroger to 'overweight' on improving fundamentals

BUZZ-Wells Fargo upgrades Kroger to 'overweight' on improving fundamentals ** Shares of department store operator The Kroger Co KR.N up 1.05% in premarket trade ** Wells Fargo upgrades stock to 'overweight' from 'equal weight,' cites improving fundamentals and "potential for a huge buyback" ** Its new rating is an equivalent to 'buy' as per LSEG da
K

Pfizer’s Wyeth reaches $39 million settlement in Effexor XR antitrust case

Pfizer’s Wyeth reaches $39 million settlement in Effexor XR antitrust case By Mike Scarcella April 10 (Reuters) - Pfizer PFE.N subsidiary Wyeth has agreed to pay $39 million to resolve claims from drug purchasers that it conspired with rival Teva to delay launching a less-expensive version of the antidepressant drug Effexor XR. Plaintiffs’ lawyers for Rochester Drug Co-Operative, Stephen L.
K
P
T
W

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.